| Name | Title | Contact Details |
|---|
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
ZoomMed inc. is a Brossard, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
AOS Research Services is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Emergency Ambulance Service is a Brea, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eastern Ct Health Network is a Manchester, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.